Skip to main content
Premium Trial:

Request an Annual Quote

Eurofins Viracor, Cleveland Clinic Sign License Deal for Kidney Transplant Rejection Biomarker Test

NEW YORK – Diagnostics company Eurofins Viracor said on Monday that it has signed a licensing agreement with the Cleveland Clinic for exclusive rights to a urine biomarker test for detecting rejection in kidney transplant patients.

The test, which was developed by Cleveland Clinic researcher Robert Fairchild and University of Alabama researchers Roslyn Mannon, identifies RNA molecules in urine that are highly accurate for the diagnosis of rejection and elevated risk of rejection in kidney transplant patients. The partners are aiming to give clinicians a way to diagnose clinical acute rejection without a biopsy and to distinguish clinical acute rejection from other non-rejection causes of kidney dysfunction after transplant.

Eurofins Viracor said it will work with Fairchild to validate the diagnostic assay for use in patient testing.

Further terms of the deal were not disclosed.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.